Nelson Bunker Curnes Purchases 5,000 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Mobia Medical, Inc. (NASDAQ:MOBI) CFO Nelson Bunker Curnes bought 5,000 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were bought at an average price of $12.79 per share, for a total transaction of $63,950.00. Following the completion of the transaction, the chief financial officer directly owned 366,997 shares in the company, valued at approximately $4,693,891.63. This represents a 1.38% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Mobia Medical Stock Performance

Shares of NASDAQ MOBI traded down $0.40 during trading on Thursday, hitting $12.32. 165,707 shares of the company were exchanged, compared to its average volume of 163,509. The firm has a market capitalization of $409.63 million, a P/E ratio of 66.00 and a beta of 2.84. Mobia Medical, Inc. has a 1 year low of $10.19 and a 1 year high of $14.77.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings results on Thursday, June 4th. The company reported $999.00 earnings per share (EPS) for the quarter. The company had revenue of $12.07 million during the quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MOBI shares. Wall Street Zen cut Mobia Medical from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. BTIG Research started coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $19.00 price objective on the stock. Wolfe Research started coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set an “outperform” rating for the company. The Goldman Sachs Group started coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $31.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $15.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $20.25.